VA-PAB-PBD features a valine-alanine protease-sensitive linker paired with a pyrrolobenzodiazepine (PBD) cytotoxin, offering high potency and selective release for antibody-drug conjugates in oncology applications. Keywords: protease-cleavable linker, PBD toxin, ADC cytotoxin, targeted cancer therapy.
Structure of 1595275-60-7
* For research and manufacturing use only. We do not sell to patients.
Size | Price | Stock | Quantity |
---|---|---|---|
-- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Catalog | Product Name | CAS | Inquiry |
---|---|---|---|
BADC-00340 | PBD dimer | 1222490-34-7 | |
BADC-00015 | MC-Val-Ala-PBD | 1342820-51-2 | |
BADC-00738 | MA-PEG4-VA-PBD | 1342820-68-1 | |
BADC-00670 | Mal-PEG4-VA-PBD | 2259318-50-6 | |
BADC-00826 | Aniline-MPB-amino-C3-PBD | 2412923-79-4 | |
BADC-00827 | Py-MPB-amino-C3-PBD | 2412924-07-1 | |
BADC-01377 | Pyrrolobenzodiazepine (PBD) | 945490-09-5 | |
BADC-00755 | DBCO-PEG4-VA-PBD |
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.